Med24
Clinical Medicine 9. 10. 2026 • 1 min read • medical-news

FDA Approves Adjuvant Atezolizumab for Certain Colon Cancers

The FDA on Thursday approved intravenous atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in patients 2 years...

FDA Approves Adjuvant Atezolizumab for Certain Colon Cancers

The **FDA** has approved intravenous **atezolizumab** in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in patients 2 years and older. Additionally, the agency approved the subcutaneous form of **atezolizumab** (with hyaluronidase) for patients 12 years and older weighing at least 88 lb.

Sponsored content

A randomized trial, ATOMIC/ML39057, involving 711 patients with stage III dMMR colon cancer, demonstrated a 50% reduction in the risk of disease recurrence or death with the addition of **atezolizumab** to standard adjuvant chemotherapy. The 3-year disease-free survival rate was 86% with atezolizumab plus chemotherapy compared to 76% with chemotherapy alone (HR 0.50, 95% CI 0.35-0.73, P<0.0001). A subgroup analysis of patients with dMMR cancer confirmed this HR of 0.53 (95% CI 0.36-0.79, P=0.0007). Grade &#8805;3 adverse events were more frequent in the atezolizumab arm (71.7% vs 62.1%). The safety profile of atezolizumab plus chemotherapy was consistent with the known effects of the drugs.

Original Scientific Source
medical-news
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement